Nanocarry Therapeutics

📍 Weizmann Science Park, Israel🗓 Founded 2021👥 8 employees💰 Last funded Feb 2021
Biotechnology Research🌐 nanocarry.com
Website LinkedIn
Nanocarry is developing a new class of therapeutics based on bioengineered nanoparticles with novel capabilities to treat oncology indications and brain diseases. Using a proprietary “Plug and Play” approach, Nanocarry’s AxS platform can be easily modified to deliver a wide array of biologics, safely and effectively, to the brain and beyond. Nanocarry’s first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Nanocarry Therapeutics?
Nanocarry Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Nanocarry Therapeutics last raise funding?
The most recent investment in Nanocarry Therapeutics recorded on gritt.io was in February 2021.
When was Nanocarry Therapeutics founded?
Nanocarry Therapeutics was founded in 2021.
What industry is Nanocarry Therapeutics in?
Nanocarry Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nanocarry Therapeutics based?
Nanocarry Therapeutics is headquartered in Weizmann Science Park, Israel.